DYADIC INTERNATIONAL INC

Regulatory Filings • Aug 1, 2006

8-K 1 form8_k080106.htm DYADIC FORM 8-K BIOTECHNOLOGY MEETING 8.01.06 Dyadic Form 8-K Biotechnology Meeting 8.01.06 Licensed to: Dyadic International, Inc. Document Created using EDGARizer HTML 3.0.4.0 Copyright 2006 EDGARfilings, Ltd., an IEC company. All rights reserved EDGARfilings.com

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 8-K

Pursuant to SECTION 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2006

Dyadic International, Inc.

(Exact name of small business issuer as specified in its charter)

Delaware	333-102629	45-0486747
(State
or other jurisdiction of
incorporation)	(Commission
File Number)	(I.R.S.
Employer Identification No.)

| 140
Intracoastal Pointe Drive, Suite 404, Jupiter,
Florida | 33477 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |

(561) 743-8333

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Dyadic International, Inc. (the “Registrant”) today will post on its website www.dyadic.com the presentation made by its scientist, Richard Burlingame, Ph.D., on August 1, 2006 at the Society for Industrial Microbiology (SIM) Industrial Microbiology and Biotechnology Meeting in Baltimore, Maryland. At the meeting, the Registrant updated its progress in the use of its C1 Expression System for the production of therapeutic proteins in filamentous fungi .

Neither the presentation nor any other information contained on the Registrant’s website is incorporated by reference into this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| | DYADIC
INTERNATIONAL, INC. |
| --- | --- |
| | (Registrant) |
| | By: |
| Date:
August 1, 2006 | Name:
Mark A. Emalfarb Title:
President and Chief Executive
Officer |